Abstract Number: PB0344
Meeting: ISTH 2022 Congress
Background: Immune Thrombocytopenic Purpura (ITP) disease destroys platelets with an autoimmune process. During this one, the count of platelets reduces increasing at the same time the risk of bleeding.
Paediatric classic treatmets for ITP includes corticosteroids, gamma globulins, splenectomy and immunosuppresive drugs like Rituximab.
Currently, the possibility of new treatments such us thrombopoietin (TPO) receiver analogues (Romiplostim y Eltrombopag) have been used as second row treatments instead of splecnetomy and Rituximab due to a better security profile for the patient.
Aims: Describe our experience with Romiplostim in paediatric patients with refractory Immune Thrombocytopenic Purpura (ITP) as first row treatment.
Methods: Data analysis of paediatric patients with ITP and Romiplostim as first row treatment from 2018 to 2021.
Results: All the patients treated with Romiplostim have achieved the complete remission (CR) without any side effects. In one of the patients, after the complete remission it was possible to stop the Romiplostim treatment.
Conclusion(s): Based in our experience with it, Romiplostim is a real alternative for patients where first row treatments have not been effective; furthermore, it has a good security profile without any side effects.
To cite this abstract in AMA style:Carranco Falcón A, Díaz Roldán B, Domínguez Rodríguez J, Velarde López Ayala P. Use of romiplostim in paediatric patients with immune thrombocytopenic purpura (ITP) [abstract]. https://abstracts.isth.org/abstract/use-of-romiplostim-in-paediatric-patients-with-immune-thrombocytopenic-purpura-itp/. Accessed February 27, 2024.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/use-of-romiplostim-in-paediatric-patients-with-immune-thrombocytopenic-purpura-itp/